Physician

Umasankar Ramadoss, MD

According to 2025 Medicare claims, Umasankar Ramadoss, MD (NPI: 1962499806) practices medical oncology in the Columbia, MO market, with the plurality of this provider's patient population coming from Boone, MO. This provider's primary affiliated billing organization is MISSOURI CANCER ASSOCIATES LLC (NPI: 1215947338; TIN: 431763016) and primary practice location at 65201-7167. Ramadoss is affiliated with the Aledade 98 MO MSSP Enhanced (ACO ID: A4998) and Aledade 93 National MSSP Enhanced (ACO ID: A5206), participating under the MSSP model.

Ramadoss' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,190 traditional Medicare patients, billed 311,596 HCPCS/CPT codes, and received $5,757,129 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,808 prescription claims across 414 beneficiaries totaling $5,587,052 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 38 claims. Open Payments data shows 119 records totaling $2,052. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,691,519 to $5,757,129. Similarly, Part D prescription costs have risen steadily, from $1,219,721 to $5,587,052. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,983 to $1,149.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	733	239,028	$2,691,519
2016	870	424,492	$3,934,387
2017	864	401,700	$4,188,307
2018	1,140	330,825	$4,025,375
2019	1,109	312,636	$3,905,753
2020	1,076	301,407	$3,867,840
2021	1,194	395,443	$4,636,823
2022	1,215	524,754	$5,914,399
2023	1,269	364,648	$4,872,940
2024	1,190	311,596	$5,757,129

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	286	2,612	$1,219,721
2016	342	3,278	$2,396,831
2017	332	3,124	$3,457,395
2018	337	3,246	$3,846,145
2019	374	3,079	$4,349,418
2020	322	2,791	$3,780,261
2021	372	2,911	$4,010,566
2022	398	2,675	$3,703,306
2023	381	2,330	$2,554,635
2024	414	2,808	$5,587,052

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	73	$7,561
2016	37	175	$50,843
2017	N/R	160	$34,782
2018	N/R	150	$11,328
2019	N/R	72	$5,802
2020	N/R	59	$5,003
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	38	$6,211
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	427	1,301	$90
96413	Administration of chemotherapy into vein, 1 hour or less	225	630	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	434	631	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	501	1,102	$12
96372	Injection of drug or substance under skin or into muscle	226	454	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	128	3,563	$2,157,340
Pomalyst	Pomalidomide	16	448	$361,060
Erleada	Apalutamide	25	750	$356,883
Venclexta	Venetoclax	17	513	$257,469
Zejula	Niraparib Tosylate	13	390	$243,008

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	119	$2,052	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Umasankar Ramadoss, MD?

Tedicare shows public-source Medicare data for Umasankar Ramadoss, MD (NPI 1962499806), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Umasankar Ramadoss, MD have ACO affiliation data?

Umasankar Ramadoss, MD is shown with ACO affiliation data for Aledade 98 MO MSSP Enhanced (MSSP, ACO ID A4998) and Aledade 93 National MSSP Enhanced (MSSP, ACO ID A5206).

What billing organization is linked to Umasankar Ramadoss, MD?

Umasankar Ramadoss, MD is linked to MISSOURI CANCER ASSOCIATES LLC (billing NPI 1215947338) in the available physician profile data.

Does Umasankar Ramadoss, MD have Open Payments data?

Umasankar Ramadoss, MD has 119 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.